Wang Jia-Qi, Deng Rong-Xin, Liu Hui, Luo Yuan, Yang Zhi-Cheng
Department of Oral and Maxillofacial Surgery, Shanghai Stomatological Hospital, Fudan University, Shanghai, China.
Gland Surg. 2020 Dec;9(6):1989-1997. doi: 10.21037/gs-20-464.
The purpose of this study was to elucidate the clinicopathological characteristics of patients with lymphoepithelial carcinoma of salivary gland (LEC-SG) and determine the factors associated with survival.
A total of 179 LEC-SG patients from the Surveillance, Epidemiology, and End Results (SEER) database between 1975 to 2016 were included. The clinicopathological characteristics and overall survival of LEC-SG patients were described, and the features affecting prognosis were further determined using Kaplan-Meier Curves and Cox survival analysis.
The median overall survival of LEC-SG patients was 206 months, and the 1-, 5-, 10- and 20-year survival rates were 91.0%, 80.2%, 66.4%, and 37.6%, respectively. The prognoses were significantly associated with age, ethnicity, marital status, tumor invasion, as well as lymph node metastases [P<0.01 for all). Surgical resection could significantly improve the prognosis of this disease (median overall survival (mOS): 219 68 months, P<0.01]. Postoperative radiotherapy could improve long-term survival and decrease the risk of death among patients who survive exceed 10-year after surgery. The Cox regression analysis showed that old age (>60 years) and lymph node metastases were independently associated with poor survival (P<0.05 for both). Conversely, the use of surgery was an independent favorable prognostic factor [hazard ratio (HR) 0.29, 95% CI: 0.13-0.66].
LEC-SG patients had a favorable prognosis with a mOS of 206 months. Old age, lymph node metastases, the use of surgery were independently associated with survival of LEC-SG patients.
本研究旨在阐明涎腺淋巴上皮癌（LEC-SG）患者的临床病理特征，并确定与生存相关的因素。
纳入了1975年至2016年间来自监测、流行病学和最终结果（SEER）数据库的179例LEC-SG患者。描述了LEC-SG患者的临床病理特征和总生存期，并使用Kaplan-Meier曲线和Cox生存分析进一步确定影响预后的特征。
LEC-SG患者的中位总生存期为206个月，1年、5年、10年和20年生存率分别为91.0%、80.2%、66.4%和37.6%。预后与年龄、种族、婚姻状况、肿瘤侵犯以及淋巴结转移显著相关（所有P<0.01）。手术切除可显著改善该疾病的预后（中位总生存期（mOS）：219对68个月，P<0.01）。术后放疗可改善长期生存，并降低术后存活超过10年患者的死亡风险。Cox回归分析显示，老年（>60岁）和淋巴结转移与生存不良独立相关（两者P<0.05）。相反，手术的使用是一个独立的有利预后因素（风险比（HR）0.29，95%CI：0.13-0.66）。
LEC-SG患者预后良好，中位总生存期为206个月。老年、淋巴结转移、手术的使用与LEC-SG患者生存独立相关。
